Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bamipine is a first-generation piperidine H1-antihistamine with anticholinergic properties, primarily used as an antipruritic ointment for the relief of mild to moderate symptoms associated with insect bites and other allergic skin conditions. It acts by blocking the histamine H1 receptor, thereby reducing the effects of histamine in allergic reactions. Bamipine also exhibits anticholinergic activity and can cause sedative effects due to its ability to cross the blood-brain barrier. The drug is typically administered topically, as it is not absorbed through intact skin in significant amounts; oral use is not common or well-documented. Its maximal topical effect occurs within 20–60 minutes and may last up to 48 hours[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bamipine.